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Urine cytology is considered a valid diagnostic method of urological and nephrological diagnosis and follow-up, whereas
immunohistochemistry is an indispensable adjunct to histopathology. The combination of both—urinary immunocytology—has, so far,
only attained a marginal role. This review gives a state-of-the-art update of urinary markers and relevant epitopes, elucidates some
methodological pitfalls, and gives an outlook on the promise of urinary immunocytology today. It suggests that morphological urine
cytology should be amended by immunology in a mutual quest of urologists and pathologists to improve the diagnostic power of urine
cytology. The cost-effectiveness of the method is considered. This review also sheds light on the age-old dispute among pathologists about
the nature of urothelial carcinoma that is reﬂected in the frequent and controversial reclassiﬁcations of the disease.
r 2014 The Authors. Published by Elsevier Inc.
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When Papanicolaou and Marshall [1] introduced urine
cytology as a diagnostic procedure in cancers of the urinary
tract, they initiated a development that rendered urine
cytology a valid diagnostic method of urological and uro-
oncological diagnosis and follow-up. Panurothelial assess-
ment, high speciﬁcity and sensitivity, cost-effectiveness, and
a stable and easy workﬂow are some of its advantageous
features. When Köhler and Milstein [2] described the ﬁrst
monoclonal antibody, they sparked an explosion in the ﬁeld
of immunology. A wide variety of diseases became under-
standable and immunological analysis has become an indis-
pensable adjunct to histopathologic diagnosis. The
combination of these 2 approaches—urinary immunocytol-
ogy—however, has a marginal role only so far. This review
gives a state-of-the-art update of relevant epitopes, elucidates.urolonc.2013.11.002
uthors. Published by Elsevier Inc.
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Open access under CC Bsome reasons and methodological pitfalls, and gives an
outlook on the promise of urinary immunocytology today.2. The urologist’s approach to urinary immunocytology
Clinical experience suggests that urothelial carcinomas
are—unlike colorectal carcinomas, e.g.—not well charac-
terized as a continuum from benign to undifferentiated
carcinoma. They can rather be divided into 2 groups.
Although a larger (470% of patients) group of low-grade
tumors have a tendency to recur but progress rarely, a
smaller group of high-grade carcinomas progress and
metastasize early and are fatal if not diagnosed and treated
early and with determination. The second group is the one
that deserves and attracts most scientiﬁc attention.
Morphological urine cytology has stood the test of time
and is consistently considered the gold standard of urine-
based diagnosis of urothelial carcinoma with unmatched
speciﬁcity and sensitivity for the detection of high-grade
tumors [3]. Its value in various clinical settings hasY-NC-ND license.
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Health Organization classiﬁcation of 2004 has been taken
into account [4]; for more recent reports see Refs. [5,6]. The
limitations of conventional morphology-based urine cytol-
ogy have been lined out (for reviews see Refs. [5–9]), and
responsible cytologists have formulated clear guidelines for
its use [10]. Morphometric approaches can add some
diagnostic information [11], but they are time consuming
or expensive (Quanticyt) and have thus been implemented
in few centers only.
For high-grade tumors, the quest for additional powerful
markers has been virulent in urology for many years. Many
promising markers have been suggested to complement or
replace urine cytology, so far with little or no additional
diagnostic power. The hype of the 1990s has long cooled
down because published results were difﬁcult to reproduce.
So far, no urine marker has been able to achieve the
speciﬁcity of urine cytology let alone replace it. Some urine
markers gained Food and Drug Administration approval on
the basis of studies designed to highlight their performance
and major drawbacks, such as excessive false-positive rates
were sometimes ignored as was the case with nuclear matrix
protein 22 (NMP22). The sobering criticism that ensued has
not deterred some urine markers from being widely
marketed, and caution is warranted when employing a
new diagnostic test [12].
Several immunocytology-based urine tests are commer-
cially available that rely on antibodies against cell surface
antigens that are commonly expressed by urothelial carci-
noma cells. The immunocytological urine test with the
widest distribution is the Immunocyt/uCytþ. For the
remainder of cases, urinary immunocytology has largely
been limited to detect and identify rare and episodic tumors
of the genitourinary tract.3. The pathologist’s approach to urinary
immunocytology
In pathology, immunocytology is an established adjunct
to morphology in many disorders, both malignant and
benign, which improves the diagnostic accuracy and also
allows the identiﬁcation of markers both for prognosis and
for targeted therapy.
Its use in detecting metastatic carcinoma [13] or neuro-
blastoma [14,15] cells in blood or bone marrow is established
while being aware of methodological limitations. In the
diagnosis of effusions that often contain few and distorted
cells, immunocytology is an accepted pivotal tool [16,17].
Current cytopathology textbooks attribute immunocytol-
ogy only a marginal role when diagnosing urothelial
carcinoma [9,16,18]. Current reviews on immunocytochem-
istry [19] and on urothelial immunohistochemistry [20] also
do not speciﬁcally mention urinary immunocytology.
It appears that immunocytology of urine, however
promising from a theoretical point of view and howevermuch is being published on the issue, has not (yet) gained
much inﬂuence, neither in urology nor in pathology.
4. What is the bottom line?
When reviewing the literature, it appears that the
markers, genes, and immunological epitopes considered
relevant for urothelial cancer are differently viewed by
pathologists and urologists (author [P ¼ pathology, U ¼
urology]): Netto (P) [21], Gakis et al. (U) [22], Burger et al.
(U) [23], Lindemann-Docter et al. (P) [24], Nawroth et al.
(P,U) [25], Skoog and Tani (P) [19], Sullivan et al. (P) [26],
Protzel and Hakenberg (U) [27], Bolenz and Loten (U) [28],
van Rhijn et al. (U) [29], and Vrooman and Witjes (U) [30].
These reviews are discussed in Ref. [31], and partly in Refs.
[32,33].5. Commercially available tests using urinary
immunocytology
ImmunoCyt/uCytþ uses 2 ﬂuorescein-coupled antibodies,
M344 and LDQ10, directed against 2 sulfated glycoproteins
and Texas Red–coupled antibody 19a211 directed against
glycosylated high-molecular-weight carcinoembryonic anti-
gen. When using it as a reﬂex test in patients with atypical
urine cytology, a negative result of ImmunoCyt predicts a
negative cystoscopy [34]. Schmitz-Dräger et al. [36] pub-
lished several studies on the value of ImmunoCyt in patients
with asymptomatic hematuria [35,36].
Although not an immunological technique, ﬂuorescence
in situ hybridization can detect genetic instability in
urothelial carcinomas that correlates with a more aggressive
behavior of the tumor. The UroVysion test uses centromeric
DNA probes of chromosomes 3, 7, and 17 plus a probe of
chromosomal region 9p21, which are labeled with distinct
ﬂuorescent dyes. With the UroVysion test, additional
diagnostic information can be expected in some carcinomas
of the upper urinary tract, admittedly a difﬁcult ﬁeld to
tackle [24,37].
Both ImmunoCyt/uCytþ and UroVysion perform
well and have been recommended as conﬁrmatory
tests [19,26,34,38,39]. If cystoscopy is negative or
equivocal, this approach can avoid biopsies and thus save
money [40]. Nonetheless commercially available immuno-
cytological urine systems have not gained widespread
acceptance in clinical routine. This is attributed to costs as
well as the considerable time consumption associated with
their use.
Calculation of the cost of the various tests depends—
among others—on the viewing angle and the system of
remuneration. Estimates are from several hundred USD for
the UroVysion (of which 90 USD are for reagents),
approximately 100 USD for the bladder tumor antigen
(BTA)/bladder tumor antigen stat (BTA stat) (30 USD for
reagents), and 60 USD for urine cytology (approximately 5
M. Böhm et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 383–390 385USD for reagents). A systematic review of cost-
effectiveness in the United Kingdom suggests that for the
initial diagnosis of bladder cancer, the strategy of urine
cytology and white light cystoscopy is less costly (GBP
1043 per patient) than the combination cystoscopy, Immu-
noCyt/uCytþ, and photodynamic diagnostics (GBP 2370
per patient), but also less effective in terms of life years
(11.59 vs. 11.66) [41].
Additional immunohistochemistry stains cost about 15 to
20 USD per antibody. This renders the strategy of standard
urine cytology plus immunocytochemistry, when needed,
versatile, cost-effective, and responsive.6. What novel markers and epitopes might be of
interest?
Hundreds of cellular pathways have been identiﬁed, and
this trend is unbroken [42]. A list of 500 pathway maps can
be accessed via www.qiagen.com/pathway-central. Many
targets relevant for the malignant potential of tumors have
thus been identiﬁed and many therapeutics directed at such
targets are being introduced, an approach termed “targeted
therapy” (for a review relating to urothelial carcinomas see
Refs. [28,43–45]). Targeted diagnostics should keep pace
with this development also in urothelial cancer to direct the
most appropriate therapy to every patient [46].
Microscopy is taking leaps toward superresolution,
optical sectioning, and 3D-microscopy. Cytology is ideal
for these approaches, because cells are isolated, i.e., the
amount of data to collect and to compute are limitable. Most
superresolution approaches rely on immunostaining.
This review focuses on markers and pathways that
can be addressed by immunological analyses and thus
complement morphological urine cytology. This approach
bears the potential to improve urine cytological diagnosis. A
number of tests have been suggested that use soluble
markers and detect them with no information of their
cellular origin. Most of the proliferation-associated markers
lack speciﬁcity because benign conditions, such as inﬂam-
mation and stones, are also related with cell proliferation.
By omitting the morphological information of the origin of
the marker from benign vs. malignant cells, the distinction
between benign and malignant conditions becomes difﬁcult.
Soluble markers are not discussed in this review for this
reason.
Cell adhesion molecules may not be ideal epitopes for
urinary immunocytology because cells must detach from their
tissue origin before they are shed into the urine and become
accessible to urine cytology. Alteration of cell adhesion
molecules on the protein level is associated with this process
irrespective of the malignant potential of the shed cells.
Cytokeratin stains are helpful [47]. This includes pancy-
tokeratin (clones AE1–AE3 and MNS116, e.g., DAKO) and
cytokeratin 20 (CK-20), a marker of umbrella cells [48], and
also cytokeratin fragments (CYFRA), in particular fragments8, 18, 19, and 21 to 1 [49]. CYFRA 8 and 18 are detected by
the urinary bladder cancer-Rapid (UBC Rapid) test, and
CYFRA 8, 18, and 19 are used in the tissue plasminogen
activator test, but both tests omit information of cellular
origin and morphology. CK-20-positive atypical urothelial
cells are indicators of low-grade urothelial carcinomas of the
lower [50,51] and upper urinary tract [52]. Urothelial
carcinomas stain positive for placental S100, GATA3,
high-molecular-weight cytokeratins (CK-7 and CK-20, in
particular), uroplakin III, and p63. Expression of both CK-20
and Ki-67 correlates with poor prognosis [53,54]. A review
of human keratins has been published [55].
Fibroblast growth factor (FGF) and its receptor (FGFR)
are markers of genetic stability [56–58]. Mutation of
FGFR3 appears to be associated with low-grade tumors
and good prognosis [59–61], mutation of p53 [62,63] and
immunhistochemical overexpression of MIB-1 with high-
grade tumors and poorer prognosis. From this a “molecular
tumor grade” has been suggested [59]. A similar approach
uses the genes FGFR3, PIK3CA, KRAS, HRAS, NRAS,
TP53, CDKN2A, and TSC 1 to distinguish low-grade from
high-grade and non–muscle-invasive from muscle-invasive
carcinomas [64]. The transformation from FGFR3-
associated superﬁcial to p53-associated invasive tumors
may be mediated via p63 and p73 [65], and mutation and
overexpression of FGFR3 are associated with less malig-
nant urothelial carcinomas in a population of Jordan [60].
The signiﬁcance of the pathway phosphatidylinositol-3-
kinase/Akt/mammalian target of rapamycin (mTOR) [66,67]
and of the pathway mTOR/AMPK/OGG1 [68] in the onco-
genesis of urothelial carcinomas have been elucidated. Staining
of molecules of the mTOR pathway and of hypoxia-inducible
factor could become relevant for personalized medicine [69], as
medication interacting with this pathway is available.
Transcription factors and nuclear matrix proteins may be
good targets to address the aggressiveness and metastatic
potential of cancer. The signiﬁcance of cyclin-dependent
kinase 4 and miR-195 [70], serine-threonine-kinase Pim-1
[71], and fatty acid synthase [72] have been addressed.
Immunohistochemical expression of serine-threonine-kinases
aurora A and aurora B is elevated in poorly differentiated
urothelial carcinomas [73]. Carbonic anhydrase 9 up-
regulation appears to indicate worse prognosis in transitional
cell carcinoma [74]. BLCA-4 overexpression appears to
indicate poor prognosis [75]. Overexpression of fascin, an
effector of the ribosomal S6 kinase 2-cAMP response element-
binding protein signaling pathway, correlates with the invasion
of urothelial carcinomas and can be detected immunologically
in urine cytology [76]. CXC-chemokine receptor-4 up-
regulation is associated with muscle invasion in bladder
cancer, and cells from muscle-invasive urothelial carcinomas
can be stained with its ﬂuorescence-coupled antagonist
TY14003 and detected in urine cytology [77].
With regard to oncoproteins and tumor suppressors
probably a combination of candidates yields additional
diagnostic information, such as a combination of cell
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Expression of p21 can—unlike other cell cycle–associated
proteins—together with clinical parameters, tumor size, and
accompanying carcinoma in situ helps predict the tendency
for recurrence of non–muscle-invasive bladder carcinomas
[79]. Immunocytochemistry of p16 (INK4a) can improve the
detection of low-grade [80] and high-grade [81] urothelial
carcinomas. The combination of appropriate markers can be
viewed as a step toward a personalized medicine [46].
Factors of angiogenesis and p53 are involved in the onco-
genesis of urothelial carcinoma but not with their invasion
[82]. Expression of tumor suppressors (p53 and p21waf1)
and factors of angiogenesis (vascular endothelial growth
factor and endoglin/CD105) can predict the tendency for
recurrence of non–muscle-invasive bladder cancer [83].
Here, the technique used can directly be transferred to urine
cytology. Urinary immunocytology of p53 and epidermal
growth factor receptor was able to detect malignancy [84],
but the combination of p53 with glutathione-S-transferase
was not [85]. Minichromosome maintenance protein-2 is
associated with cell proliferation, and urinary immunocytol-
ogy has been used as an adjunct to urine cytology [86].
LIM-and-SH3-domain-protein-1 (LASP-1) is an actin-
binding protein involved in cell migration and regulation of
the cytoskeleton. Its detection in urine has been propagated
as a prognostic soluble urinary marker [87,88], but LASP-1
immunocytology is feasible.Table
Epitopes that have been used in urinary immunocytology. FISH is included beca
Test/epitope References Finding
Cytology Tilki et al. [103] Reviews
FISH, UroVysion Parker et al. [47]
ImmunoCyt/uCytþ Proctor et al. [33]
Sullivan et al. [26]
Goodison et al. [32]
p16INK4a Alameda et al. [80] Detection of low-grade
CXCR4 Nishizawa et al. [77] Detection of high-grade
Fascin McKnight et al. [76] Predicts invasiveness
CK-20 Mai et al. [52] Detection of urothelial c
Srivastava et al. [104]
Morsi et al. [105]
Golijanin et al. [106]
Bhatia et al. [51]
p53 and EGFR Ikeda et al. [84] Detection of malignancy
p53 and GST Oǧuztüzün et al. [85] Not helpful
MMP-2 Saeb-Parsy et al. [86] Detection of bladder can
Reactive oxygen
species (ROS)
cytology
Shimada et al. [90] Increases sensitivity of c
PAX2 Herlitz et al. [97] Differentiation of benign
nephrogenic adenoma
TCC ()
PSA, HMW-CK Mai et al. [92] Differentiation of malign
in urine, PCA vs. TC
CXCR4 ¼ CXC-chemokine receptor-4; EGFR ¼ epidermal growth factor r
S-transferase; HMW-CK ¼ high-molecular-weight cytokeratins; MMP-2 ¼ ma
PSA ¼ prostate-speciﬁc antigen; TCC ¼ transitional cell carcinoma.A number of tests have been suggested to improve the
detection of low-grade urothelial carcinoma. Staining for
CD44 is negative in contrast to normal urothelium and
reactive atypia [20], and absent expression of variant
CD44v6 expression is an independent adverse predictor of
urothelial bladder cancer recurrence and overall survival
[89]. Fluorescence staining of hydrogen peroxide indicates
the urothelial production of reactive oxygen species. This
helps detect low-grade urothelial carcinomas in urine
cytology [90]. Immunohistochemical expression of vimen-
tin distinguishes low-grade transitional cell carcinomas
(negative) from reactive renal tubular cells (positive) [91].
Last, but not least, urinary immunocytology for prostate-
speciﬁc antigen and high-molecular-weight cytokeratins have
been used to deﬁne the origin of malignant cells in urine [92].
This short synopsis of some of the more promising
epitopes must be incomplete and subject to constant
updating as research progresses. At this point, studies on
urinary immunocytology are scarce. Often data on perform-
ance or diagnostic power are not provided or not yet
available. For this reason, the authors have refrained from
a ranking. Time will tell which cocktail of candidates will
generate additional diagnostic information beyond the
morphological categories “low grade” and “high grade.”
Some of the markers mentioned have already been used
in urine cytology, and these are compiled in the Table.
Others have been used on tissue sections, but bear theuse it ultilizes cellular information
Sensitivity (%) Speciﬁcity (%) n
12–90 78–100
30–100 69–96
50–100 62–85
tumors 67–75 46–83 83
tumors N/A N/A N/A
N/A N/A 35
arcinomas 27 100 30
70 71 59
80 78 50
82 77 174
N/A N/A 14
95 N/A 108
None None 124
cer 60–86 52–90 497
ytology 64–100 97 50
(þ) from
N/A N/A N/A
ant cells
C
N/A N/A N/A
eceptor; FISH ¼ ﬂuorescence in situ hybridization; GST ¼ glutathione
trix metalloproteinase-2; PAX2 ¼ paired box 2; PCA ¼ prostate cancer;
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implement urinary immunocytology of these (and other)
epitopes into the diagnosis and treatment of urothelial
cancer. It is suggested that morphological urine cytology
be complemented by immunocytology in a concerted effort
by both urologists and pathologists to improve the diag-
nostic power of urine cytology.
It is apparent that the epitopes considered relevant in
urothelial cancer [21,33,93], i.e., those that bear potential as
prognostic markers, are different from those used in most of
the bladder cancer tests that are currently being marketed.
This may be in part to explain their modest performance.
Possibly, an altered viewing angle on the underlying path-
ways to urothelial malignancy that are being meticulously
compiled by pathologists [44] may help deﬁne more power-
ful markers of urothelial malignancy. The authors maintain
that urinary immunocytology is a tool to achieve this.7. Nonmalignant conditions:
Immunocytology or immunocytochemistry can help in
the diagnosis of viral urinary tract infections that today
often go undiagnosed or maldiagnosed as “dysuria” or
“pelvic dysfunction” and are hence maltreated.
Simian vacuolating virus 40 immunostaining is a good
standard to detect infection with polyoma virus (BK-virus)
in patients with kidney transplants [94]. It complements the
detection of decoy cells in these patients. Concomitant
infected urothelial carcinomas—kidney transplant recipients
have a higher risk of being diagnosed with urothelial
carcinomas—are difﬁcult to differentiate [95], but diagnos-
tic accuracy can be improved in these cases with additional
staining (proliferating cell nuclear antigen, p53, and retino-
blastoma) [96]. Staining for renal transcription factor PAX2
differentiates between benign nephrogenic adenoma (pos-
itive) and transitional cell carcinoma (negative) [97]).
Immunostaining of CD3-positive cells in urine is an
indication of transplant rejection [98].
In urine cytology, virus-induced alterations can be
difﬁcult to distinguish from malignancy-associated alter-
ations [99], which trouble even experienced cytologists.
This results in a relevant interobserver variability, because
of both interfering difﬁcult diagnoses such as viral infec-
tions [99] and insufﬁciently deﬁned morphological criteria
[100]. Immunocytology for virus-speciﬁc epitopes could
help here.8. Complementation is the key
A histopathologist would not base a diagnosis on an
immunostaining alone but rather in conjunction with the
morphology. She or he would not use either hematoxylin
and eosin staining or immunostaining, but rather start with
hematoxylin and eosin and complement it with immuno-
histochemistry as needed. Likewise, a urine cytologistshould not found his diagnosis on one marker vs. the other.
Possibly this is a reason why so many potential urinary
markers of malignancy have failed clinical application:
They were designed to replace rather than to complement
conventional urine cytology, i.e., they do not use the
morphology of the urothelial cells and the information that
can be mined from it to fortify the test result. By not using
morphological information, they weaken their diagnostic
power. A complementing approach appears promising in
gynecological cytology [101]. Accordingly, the combina-
tion of cytomorphologic analysis as the initial screening test
with the cell-based ImmunoCyt/uCytþ and UroVysion as
reﬂex or conﬁrmatory tests has been recommended
[19,26,34,39] share this view. Complementation implies
that cell-based rather than soluble markers be used, because
only cell-based markers allow the comparison with mor-
phology. Here, immunostains give an idea not only of the
presence or absence of an epitope but also of its amount and
of its intracellular distribution.
The workﬂow of immunocytology is not much different
from immunohistochemistry, the latter being a versatile and
cost-effective adjunct to histological diagnosis. Urinary
immunocytology bears the potential to become just a
valuable adjunct to the cytological diagnosis of urine. The
impulse of this review is to utilize the accumulated expertise
in immunostaining to improve the power of urine cytology.
When standard urine cytology (which is performed by
many urologists) is complemented by immunocytology (a
primary focus of pathologists), this may also further
improve the interdisciplinary cooperation between these 2
ﬁelds of medicine beneﬁting the patient. It may also shed
more light on the emerging molecular genetic mechanisms
of bladder cancer tumorigenesis [44].
With this in mind urinary immunocytology may con-
tribute 3-fold to patient care: (1) it may add diagnostic
power, (2) it may contribute to the scientiﬁc understanding
of urothelial disorders, notably cancers, possibly better than
a consensus-oriented approach, and (3) it may help resolve
an age-old dispute among histopathologists whether low-
malignant papillary lesions need to be classiﬁed as “carci-
noma” vs. “papilloma” or “PUNLMP” on the one hand, and
whether ﬂat lesions are to be termed “carcinoma in situ”
implying malignant potential on the extreme vs. “denuding
cystitis” on the other hand. The quest is to identify the
“true” cancers [102], i.e., those that kill the patient, and one
should always be aware that a diagnosis is not so much to
satisfy the cytologist but to aid the clinician and to guide the
patient.
Cytology reports should, notwithstanding a detailed
description of the ﬁndings (for a suggestion see Ref.
[26]), come as near as possible to 1 of 3 conclusions that
entail clinical implication: (1) negative or no malignancy,
patient needs no further follow-up; (2) equivocal or
dubious, a control investigation is warranted; and (3)
suspicious of malignancy, further investigations are
required to conﬁrm the diagnosis, locate the tumor, and
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most from an immunocytological approach.
A point raised in Ref. [102] is the clinical setting in which
urine cytology is employed. In a community care or screen-
ing setting most patients do not have urothelial carcinomas,
and the challenge is to not miss a lesion. Here it is possibly
better to overinterpret, i.e., to aim for high sensitivity and
trade it for a lower positive predictive value. In a cancer
center or referral setting where the diagnosis has already been
made in many patients, the opposite may be preferential.9. Conclusion
All this implies that a novel, wider approach to urinary
immunocytology is warranted. The combination of mor-
phology and immunology bears the potential to fortify the
diagnostic power of urine cytology, as it has done in
histopathology. The identiﬁcation of relevant epitopes and
the delineation of adequate technique should become a
mutual quest of urologists and pathologists, and a combined
effort may lead to both a better understanding of the nature
of urothelial carcinoma and improved patient care.
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